Search clinical trials for: EMPAGLIFLOZIN PLACEBO

Total 54008 results

AstraZeneca

Recruiting

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Type 2 Diabetes Mellitus (T2DM)

China
Inventiva Pharma

Active, not recruiting

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus (LEGEND)

Diabetes Mellitus, Type 2 | NASH - Nonalcoholic Steatohepatitis

United States, Belgium, France, Netherlands, United Kingdom
Metacrine, Inc.

Active, not recruiting

Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

Diabetes | Fatty Liver | Type 2 Diabetes | NAFLD | NASH - Nonalcoholic Steatohepatitis | Diabetes Type 2 | NASH | Fatty Liver, Nonalcoholic

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Argentina, Croatia, Estonia, Germany, Italy, Korea, Republic of, Lithuania, Romania, Russian Federation, Slovakia, Sweden, Taiwan, Ukraine
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Type2 Diabetes

Korea, Republic of
Tel-Aviv Sourasky Medical Center

Unknown

Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study Protocol

Diabetes Mellitus, Type 2 | Weight Loss | Frailty | Sarcopenia

Israel
Boehringer Ingelheim

Completed

Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets

Healthy

Germany
Medical University of Lodz

Recruiting

Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease

Chronic Kidney Disease stage3

Poland
University of Leicester
University Hospitals, Leicester; Loughborough University

Completed

SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation. (SEESAW)

Diabetes Mellitus, Type 2

United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

Diabetes Mellitus, Type 2

United States, Canada, Greece, India, Philippines, Thailand, Ukraine
Sadat City University
Beni-Suef University

Completed

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Diabete Type 2

Egypt
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Type 2 Diabetes

United States, Hungary, Mexico, South Africa, Romania, Poland
Amir Moheet

Recruiting

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Cystic Fibrosis | Cystic Fibrosis-related Diabetes

United States
The Deutsche Diabetes Forschungsgesellschaft e.V.
Boehringer Ingelheim

Completed

Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes (EmLiFa)

Type 2 Diabetes | Non-alcoholic Fatty Liver Disease

Germany
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.

Diabetes Mellitus, Type 2

Korea, Republic of
Handok Inc.

Completed

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

Type 2 Diabetes Mellitus

Korea, Republic of
Karolinska Institutet
Karolinska University Hospital

Recruiting

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes (DiaSpax)

Type 2 Diabetes

Sweden
SINA Health Education and Welfare Trust

Completed

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

Polycystic Ovary Syndrome | Weight Gain | HbA1c

Pakistan
Rambam Health Care Campus
Boehringer Ingelheim

Unknown

Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients (ERA-HF)

Heart Failure | Diabetes Mellitus | Arrythmia
AstraZeneca

Completed

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

United States, Canada, Czechia, Germany, Russian Federation, Mexico
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379

Type 2 Diabetes Mellitus

Korea, Republic of
Beni-Suef University

Recruiting

of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

PCO

Egypt
Yale University
AstraZeneca

Not yet recruiting

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

Breast Cancer | Hyperinsulinism | HER2-negative Breast Cancer

United States
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical...

Recruiting

Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study

Metabolic Associated Fatty Liver Disease

Taiwan
Amsterdam UMC, location VUmc

Withdrawn

REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations (REGROUP)

Diabetes Mellitus, Type 2 | Chronic Kidney Diseases
University Hospital Goettingen
German Research Foundation

Recruiting

Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients (DOUBLE_PROTECT)

Chronic Kidney Failure in Children and Young Adults

Germany
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Effect of Dapagliflozin on VT in Patients With Heart Failure.

Heart Failure
University of Sao Paulo General Hospital
Federal University of São Paulo

Recruiting

EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.

Diabetes Mellitus, Type 2 | Diabetes Complications | Kidney Transplantation

Brazil
The TIMI Study Group
AstraZeneca; Worldwide Clinical Trials

Recruiting

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

Heart Failure | Acute Heart Failure

United States
Tan Tock Seng Hospital

Withdrawn

Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease (DECODED)

Cardiovascular Diseases | End Stage Renal Disease
Mariëlle Scheffer
AstraZeneca

Unknown

Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction (STADIA-HFpEF)

Heart Failure, Diastolic

Netherlands
The Catholic University of Korea
AstraZeneca; Severance Hospital; Eulji General Hospital; Kyung Hee University Hospital...

Completed

Effect of Dapagliflozin on Glycemic Variability (DIVE)

Type 2 Diabetes Mellitus

Korea, Republic of
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes | High Blood Sugar

Japan
AstraZeneca
Bristol-Myers Squibb

Completed

Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

Type 2 Diabetes

United States, Bulgaria, Russian Federation, United Kingdom, Hungary, Romania, Finland, Canada, Austria, Germany, Netherlands, Slovakia, Spain
AstraZeneca
Bristol-Myers Squibb

Completed

Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

Japan
AstraZeneca
Bristol-Myers Squibb

Suspended

Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone

Type 2 Diabetes

India
University of Utah
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

Hemodialysis | Kidney Disease, Chronic | Kidney Failure | Dialysis | Diabetic | End-stage Kidney Disease | Kidney Dysfunction | Non-diabetic

United States
Boehringer Ingelheim

Completed

Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects

Healthy
Seoul National University Bundang Hospital

Recruiting

Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety (Location-F)

Diabetes Type 2

Korea, Republic of
AstraZeneca

Recruiting

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

Chronic Kidney Disease With High Proteinuria

United Kingdom, Argentina, Italy, United States, Poland, Germany, Spain, Denmark, Sweden, France, China, Taiwan, Thailand, Vietnam, Brazil, Malaysia, Mexico, Philippines, Israel, Norway, Korea, Republic of, Canada, Japan, Turkey, Australia and more
Seoul National University Bundang Hospital

Recruiting

Effect of Empagliflozin on Body Composition and Ketones

Diabetes Mellitus | Fat; Intolerance, Pancreas

Korea, Republic of
University Hospital, Gentofte, Copenhagen

Completed

Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion (Px-Meal)

Diabetes After Total Pancreatectomy

Denmark
Kun Hua

Recruiting

Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure (DETAIL-CMIV)

Atrial Fibrillation | Atrial Fibrillation Recurrence | Cox Maze IV | Patients With or Without Heart Failure and Diabetes

China
Nanfang Hospital, Southern Medical University

Completed

Dapagliflozin Efficacy and Action in NASH (DEAN)

Nonalcoholic Steatohepatitis

China
Medical University of Vienna

Unknown

Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism

Type 2 Diabetes | Metabolically Healthy Controls

Austria
AstraZeneca
Bristol-Myers Squibb

Completed

Dapagliflozin DPPIV Inhibitor add-on Study

Type 2 Diabetes

United States, Germany, Poland, Argentina, United Kingdom, Mexico
AstraZeneca
Bristol-Myers Squibb

Completed

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Hypertension | Cardiovascular Disease | Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

United States, Vietnam, Germany, Romania, Canada, Argentina, Slovakia, Taiwan, Spain
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Type 2 Diabetes Mellitus, CKD and Albuminuria

United States, Spain, Canada, Korea, Republic of, Mexico, Japan, Taiwan, Australia, South Africa

Search clinical trials for: EMPAGLIFLOZIN PLACEBO

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations